188 EAST BLAINE STREET, SUITE 400, SEATTLE, WA
Material disclosure
Changes in Board, Management or Compensation
Reports Second Quarter 2025 Financial Results and Business Updates
Announces Pricing of Public Offering
Earnings Release
Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
Submission of Matters to a Vote of Security Holders
Financial Results, Other Events
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement
Free Writing Prospectus
Amended Notice of Proposed Sale of Securities